Drug Approval | August 02, 2021
Clinical trials in the UK to study the efficacy of Ashwagandha on COVID 19 patients
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
Ayush Ministry will conduct the study along with the UK’s London School of Hygiene and Tropical Medicine
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The distribution agreement is effective from 1 October 2021 and applies to Bormed products used in pharmaceutical packaging, medical and diagnostic devices
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The company plans to enter the EU markets in FY22
Apart from the above, it was also decided that Basic Customs Duty on import of COVID-19 vaccines be also exempted with immediate effect for a period of 3 months
_256_384.jpeg)
Against the present demand from 20 states of 6,785 MT/day of Liquid Medical Oxygen, the Government of India has from 21st April allocated 6,822 MT/day to these states
Report outlines the wide array of investment opportunities in various segments of India’s healthcare sector
Besides powering the drug discovery efforts, phytopharmaceuticals have a huge potential to create a niche market for itself, thereby helping to expand the bio-economy.
Subscribe To Our Newsletter & Stay Updated
